Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
Sponsors
Nanjing IASO Biotechnology Co., Ltd.
Conditions
Multiple Myeloma
Phase 1
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Not yet recruitingNCT05181501
Start: 2022-04-30End: 2039-04-30Target: 20Updated: 2022-01-06
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruitingNCT05698303
Start: 2023-05-08End: 2026-01-15Target: 12Updated: 2023-01-26